Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
JUBILANT PHARMA from Merelbeke-Melle, company number BE0865497049, closed financial year 2025 with a result of € -12,772 after tax. Compared with financial year 2024, the result moved from € -18,178 to € -12,772. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 6, 2025.
€ 17.6 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12,772
▲ 30 % less loss than in 2024
Profit after tax over the fiscal year.
€ 362
▼ 76% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 1.5 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 5,154
▼ 29% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € -7,920 | € -8,282 | € -18,178 | € -12,772 | ▲ € 5,406 |
| Equity | € 17,679,754 | € 17,671,471 | € 17,653,293 | € 17,640,521 | |
| Total debts | € 46,929 | € 55,211 | € 76,784 | € 86,523 | ▲ 13% |
| Cash | - | - | € 1,539 | € 362 | ▼ 76% |
| Retained profit | € 1,499,754 | € 1,491,471 | € 1,473,293 | € 1,460,521 | ▼ 1% |
| Balance sheet total | € 17,726,682 | € 17,726,682 | € 17,730,077 | € 17,727,044 |
Key figures of JUBILANT PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to JUBILANT PHARMA?
What happened at JUBILANT PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Sanjeev Rajapi Dr. Jaidev stepped down as director. NBB
- Rajesh Bhatia stepped down as director. NBB
- Michael Van Ohlen stepped down as director. NBB
- Guiliano Perfetti stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 12,772. Source: NBB ↗
- Michael Van Ohlen became a director. NBB
- Sanjeev Rajapi Dr. Jaidev became a director. NBB
- Rajesh Bhatia became a director. NBB
In short
From € 7,920 loss in 2022 to € 12,772 loss in 2025.
A new publication or filing at JUBILANT PHARMA? We notify you, reason included.
Follow JUBILANT PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 99.8% of Jubilant Pharmaceuticals NV and 99.5% of PSI SUPPLY NV itself.
Directors
According to the 2025 annual accounts
Sanjeev Rajapi Dr. Jaidev
Director
since 2023 · until 2028
since 2023 · until 2028
since 2023 · until 2028
Guiliano Perfetti
Director
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Guldensporenpark 22
9820 Merelbeke-Melle
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0865.497.049
- VAT number
- BE 0865.497.049
- Registered office
- Guldensporenpark 22, 9820 Merelbeke-Melle
- Names & denominations
- JUBILANT PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 May 2004
- Peppol
- Active · Active since 22 Dec 2025